The effect of R162 appears to be dependent on GDH1, as demonstrated by another study showing that the combination of R162 and FMK (an inhibitor of the pro-metastatic kinase RSK2) synergistically suppressed invasion and sensitized cancer cells to anoikis, an effect that was abolished in cells lacking GDH1 or RSK2.55 This evidence concerns the gene RPS6KA3 and cancer.